|
US5382574A
(en)
|
1989-12-21 |
1995-01-17 |
Novo Nordisk A/S |
Insulin preparations containing nicotinic acid or nicotinamide
|
|
DK39892D0
(da)
|
1992-03-25 |
1992-03-25 |
Bernard Thorens |
Peptid
|
|
US6284727B1
(en)
|
1993-04-07 |
2001-09-04 |
Scios, Inc. |
Prolonged delivery of peptides
|
|
DE69529998D1
(de)
*
|
1994-12-23 |
2003-04-24 |
Novo Nordisk As |
Glp-1 zusammensetzungen mit verlängerter wirkdauer
|
|
US5869602A
(en)
|
1995-03-17 |
1999-02-09 |
Novo Nordisk A/S |
Peptide derivatives
|
|
US5650386A
(en)
|
1995-03-31 |
1997-07-22 |
Emisphere Technologies, Inc. |
Compositions for oral delivery of active agents
|
|
DE19530865A1
(de)
|
1995-08-22 |
1997-02-27 |
Michael Dr Med Nauck |
Wirkstoff sowie Mittel zur parenteralen Ernährung
|
|
DE122009000079I2
(de)
|
1996-08-30 |
2011-06-16 |
Novo Nordisk As Novo Alle |
Glp-1 derivate
|
|
EP0880969A1
(en)
|
1997-05-28 |
1998-12-02 |
Applied Research Systems ARS Holdings N.V. |
Pharmaceutical compositions of peptides having low solubility in physiological medium
|
|
AU2610899A
(en)
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
N-terminally modified glp-1 derivatives
|
|
DE69916811T2
(de)
|
1998-02-27 |
2005-04-14 |
Novo Nordisk A/S |
Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden
|
|
AU3247799A
(en)
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
|
EP1060191B1
(en)
|
1998-02-27 |
2010-04-28 |
Novo Nordisk A/S |
Derivatives of glp-1 analogs
|
|
WO2000015224A1
(en)
*
|
1998-09-17 |
2000-03-23 |
Eli Lilly And Company |
Protein formulations
|
|
AU3357800A
(en)
|
1999-02-05 |
2000-08-25 |
Emisphere Technologies, Inc. |
Method of preparing alkylated salicylamides
|
|
AU3957400A
(en)
|
1999-04-16 |
2000-11-02 |
Novo Nordisk A/S |
Dry, mouldable drug formulation
|
|
AU2001275231A1
(en)
|
2000-06-02 |
2001-12-11 |
Emisphere Technologies, Inc. |
Method of preparing salicylamides
|
|
US6573237B2
(en)
|
2001-03-16 |
2003-06-03 |
Eli Lilly And Company |
Protein formulations
|
|
JP2005506956A
(ja)
|
2001-06-01 |
2005-03-10 |
イーライ・リリー・アンド・カンパニー |
長時間作用性glp−1製剤
|
|
AU2003208945B2
(en)
|
2002-02-20 |
2008-05-01 |
Emisphere Technologies, Inc |
Method for administering GLP-1 molecules
|
|
CN1787830A
(zh)
*
|
2003-05-14 |
2006-06-14 |
爱密斯菲尔科技公司 |
用于传送肽yy和pyy激动剂的组合物
|
|
MXPA05012278A
(es)
*
|
2003-05-14 |
2006-02-10 |
Emisphere Tech Inc |
Composiciones para suministrar peptido yy y combatientes pyy.
|
|
EP1670515A2
(en)
|
2003-09-19 |
2006-06-21 |
Novo Nordisk A/S |
Albumin-binding derivatives of therapeutic peptides
|
|
CN101665538A
(zh)
|
2003-12-18 |
2010-03-10 |
诺沃挪第克公司 |
与白蛋白样物质相连的新glp-1类似物
|
|
JP2007537141A
(ja)
|
2003-12-18 |
2007-12-20 |
ノボ ノルディスク アクティーゼルスカブ |
新規なglp−1化合物
|
|
US20060286129A1
(en)
|
2003-12-19 |
2006-12-21 |
Emisphere Technologies, Inc. |
Oral GLP-1 formulations
|
|
EP1750754A4
(en)
|
2004-03-31 |
2010-09-22 |
Centocor Ortho Biotech Inc |
HUMAN GLP-1 MIMETIC BODIES, COMPOSITIONS, METHODS AND USES
|
|
CN1968919A
(zh)
*
|
2004-04-16 |
2007-05-23 |
爱密斯菲尔科技公司 |
用于递送活性剂的8-(2-羟基苯氧基)辛基二乙醇胺和其盐
|
|
CA2563335A1
(en)
|
2004-04-16 |
2005-12-08 |
Emisphere Technologies, Inc. |
8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents
|
|
NZ550894A
(en)
*
|
2004-05-06 |
2011-02-25 |
Emisphere Tech Inc |
Solid dosage form of wetted heparin
|
|
TW200611704A
(en)
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
|
ES2542228T3
(es)
|
2004-07-08 |
2015-08-03 |
Novo Nordisk A/S |
Marcas de prolongación polipeptídica que comprenden un resto de tetrazol
|
|
CN105708787A
(zh)
|
2004-07-12 |
2016-06-29 |
爱密斯菲尔科技公司 |
用于递送肽yy和pyy激动剂的组合物
|
|
JP2008515856A
(ja)
|
2004-10-07 |
2008-05-15 |
ノボ ノルディスク アクティーゼルスカブ |
遅延性glp−1化合物
|
|
JP5107713B2
(ja)
|
2004-10-07 |
2012-12-26 |
ノヴォ ノルディスク アー/エス |
遅延性のエキセンディン−4化合物
|
|
EP1817008B1
(en)
|
2004-11-09 |
2020-04-01 |
Board of Regents, The University of Texas System |
Stabilized hme composition with small drug particles
|
|
JP2008525452A
(ja)
|
2004-12-22 |
2008-07-17 |
イーライ リリー アンド カンパニー |
Glp−1類似体融合蛋白質製剤
|
|
KR20070090036A
(ko)
|
2004-12-22 |
2007-09-04 |
센토코 인코포레이티드 |
Glp-1 작용제, 조성물, 방법 및 용도
|
|
JP5175553B2
(ja)
*
|
2005-02-01 |
2013-04-03 |
エミスフェアー・テクノロジーズ・インク |
胃内滞留および制御放出型送達系
|
|
TWI362392B
(en)
|
2005-03-18 |
2012-04-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
|
ES2484796T3
(es)
|
2005-03-18 |
2014-08-12 |
Novo Nordisk A/S |
Compuestos de GLP-1 extendidos
|
|
EP1909824B1
(en)
|
2005-04-08 |
2011-05-18 |
Amylin Pharmaceuticals, Inc. |
Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent
|
|
JP2009526750A
(ja)
|
2005-12-22 |
2009-07-23 |
セントカー・インコーポレーテツド |
Glp−1アゴニスト、組成物、方法および使用
|
|
WO2007121318A2
(en)
|
2006-04-12 |
2007-10-25 |
Emisphere Technologies, Inc. |
Formulations for delivering insulin
|
|
US8679540B2
(en)
|
2006-06-09 |
2014-03-25 |
Flamel Technologies |
Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications
|
|
KR20090039787A
(ko)
|
2006-07-18 |
2009-04-22 |
센토코 인코포레이티드 |
인간 glp-1 모방체, 조성물, 방법 및 용도
|
|
EP2068910A2
(en)
|
2006-08-04 |
2009-06-17 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and exendin agonists and glp-1 receptor agonists for altering lipoprotein particle size and subclass composition
|
|
EP2066337A2
(en)
|
2006-08-04 |
2009-06-10 |
Amylin Pharmaceuticals, Inc. |
Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen
|
|
US20090318353A1
(en)
|
2006-08-25 |
2009-12-24 |
Novo Nordisk A/S |
Acylated Exendin-4 Compounds
|
|
MX2009002121A
(es)
|
2006-09-07 |
2009-05-20 |
Hoffmann La Roche |
Proceso para la manufactura del acido n-(8-[2-hidroxibenzoil]-amin o)caprilico.
|
|
WO2008070543A1
(en)
*
|
2006-12-01 |
2008-06-12 |
Emisphere Technologies Inc. |
Improved acyclovir formulations
|
|
AR064623A1
(es)
|
2006-12-21 |
2009-04-15 |
Centocor Inc |
Uso de agonistas del receptor de glp -1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
|
|
US20100080829A1
(en)
|
2007-04-11 |
2010-04-01 |
Cephalon France |
Lyophilized pharmaceutical compositions and methods of making and using same
|
|
EP1980245A1
(en)
|
2007-04-11 |
2008-10-15 |
Cephalon France |
Bilayer lyophilized pharmaceutical compositions and methods of making and using same
|
|
GB0707662D0
(en)
*
|
2007-04-20 |
2007-05-30 |
Astrazeneca Ab |
Chemical compounds
|
|
US20100292133A1
(en)
|
2007-09-05 |
2010-11-18 |
Novo Nordisk A/S |
Truncated glp-1 derivaties and their therapeutical use
|
|
US20100261637A1
(en)
|
2007-09-05 |
2010-10-14 |
Novo Nordisk A/S |
Peptides derivatized with a-b-c-d- and their therapeutical use
|
|
EP2190872B1
(en)
|
2007-09-05 |
2018-03-14 |
Novo Nordisk A/S |
Glucagon-like peptide-1 derivatives and their pharmaceutical use
|
|
JP2011506442A
(ja)
|
2007-12-11 |
2011-03-03 |
コンジュケム バイオテクノロジーズ インコーポレイテッド |
インスリン分泌性ペプチド結合体の製剤
|
|
JP2009274983A
(ja)
|
2008-05-14 |
2009-11-26 |
Kowa Co |
ニコチン酸アミドを含有する経口医薬組成物
|
|
US8071537B2
(en)
|
2008-06-25 |
2011-12-06 |
Endo Pharmaceuticals Solutions Inc. |
Implantable device for the sustained release of a polypeptide
|
|
CN102123697B
(zh)
|
2008-08-18 |
2015-06-10 |
安特拉贝欧有限公司 |
用于口服给予蛋白质的方法和组合物
|
|
EP3685837A1
(en)
|
2008-09-04 |
2020-07-29 |
Amylin Pharmaceuticals, LLC |
Sustained release formulations using non-aqueous carriers
|
|
US8425968B2
(en)
|
2009-06-19 |
2013-04-23 |
Pepsico., Inc. |
Beverage preservative system containing pimaricin-cyclodextrin complex
|
|
US20120065255A1
(en)
*
|
2009-10-19 |
2012-03-15 |
Nagesh Palepu |
Cabazitaxel formulations and methods of preparing thereof
|
|
JP5832439B2
(ja)
|
2009-11-13 |
2015-12-16 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
Glp−1アゴニスト、インスリン及びメチオニンを含む薬学的組成物
|
|
SG10201500871TA
(en)
|
2009-11-13 |
2015-04-29 |
Sanofi Aventis Deutschland |
Pharmaceutical composition comprising a glp-1 agonist and methionine
|
|
US20120329711A1
(en)
|
2009-12-16 |
2012-12-27 |
Nordisk A/S |
Glp-1 receptor agonist compounds with a modified n-terminus
|
|
EP2512454A2
(en)
|
2009-12-16 |
2012-10-24 |
Nod Pharmaceuticals, Inc. |
Compositions and methods for oral drug delivery
|
|
EP2538945A4
(en)
*
|
2010-02-24 |
2013-07-24 |
Emisphere Tech Inc |
Oral b12 therapy
|
|
WO2011109784A1
(en)
|
2010-03-05 |
2011-09-09 |
Conjuchem, Llc |
Formulation of insulinotropic peptide conjugates
|
|
JP6231386B2
(ja)
|
2010-11-09 |
2017-11-15 |
ノヴォ ノルディスク アー/エス |
リンカーを有する二重アシル化されたglp−1誘導体
|
|
MX377589B
(es)
|
2010-12-16 |
2025-03-10 |
Novo Nordisk As |
Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
|
|
CN102718858B
(zh)
|
2011-03-29 |
2014-07-02 |
天津药物研究院 |
胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
|
|
AU2012241894B2
(en)
|
2011-04-12 |
2015-12-03 |
Novo Nordisk A/S |
Double-acylated GLP-1 derivatives
|
|
US20140220134A1
(en)
|
2011-06-24 |
2014-08-07 |
Astrazeneca Pharamceuticals LP |
Method for treating diabetes with extended release formulation of glp-1 receptor agonists
|
|
JP6006309B2
(ja)
|
2011-07-08 |
2016-10-12 |
アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc |
作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
|
|
HUE064694T2
(hu)
*
|
2012-03-22 |
2024-04-28 |
Novo Nordisk As |
Továbbítószert tartalmazó készítmények és elõállításuk
|
|
KR102072202B1
(ko)
*
|
2012-03-22 |
2020-01-31 |
노보 노르디스크 에이/에스 |
Glp-1 펩티드의 조성물 및 그것의 제조
|
|
WO2013189988A1
(en)
*
|
2012-06-20 |
2013-12-27 |
Novo Nordisk A/S |
Tablet formulation comprising a peptide and a delivery agent
|
|
US20150157619A1
(en)
|
2012-07-10 |
2015-06-11 |
Takeda Pharmaceutical Company Limited |
Pharmaceutical preparation for injection
|
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
HUE035803T2
(en)
|
2012-12-21 |
2018-05-28 |
Sanofi Sa |
Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
|
|
RS58039B1
(sr)
|
2013-05-02 |
2019-02-28 |
Novo Nordisk As |
Oralno doziranje glp-1 jedinjenja
|
|
CN103405753B
(zh)
|
2013-08-13 |
2016-05-11 |
上海仁会生物制药股份有限公司 |
稳定的促胰岛素分泌肽水针药物组合物
|
|
TW201609798A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
Exendin-4胜肽類似物
|
|
EP3080154B1
(en)
|
2013-12-13 |
2018-02-07 |
Sanofi |
Dual glp-1/gip receptor agonists
|
|
AR099569A1
(es)
|
2014-02-28 |
2016-08-03 |
Novo Nordisk As |
Derivados de insulina y los usos médicos de estos
|
|
WO2015155151A1
(en)
|
2014-04-07 |
2015-10-15 |
Novo Nordisk A/S |
Double-acylated glp-1 compounds
|
|
DK3006045T3
(en)
|
2014-10-07 |
2017-07-17 |
Cyprumed Gmbh |
Pharmaceutical formulations for oral administration of peptide or protein drugs
|
|
WO2016120380A1
(en)
|
2015-01-29 |
2016-08-04 |
Novo Nordisk A/S |
Pharmaceutical composition for oral glp-1 administration comprising a tablet core and immediate release coating
|
|
WO2016203495A1
(en)
|
2015-06-16 |
2016-12-22 |
Sun Pharma Advanced Research Company Limited |
Long acting liraglutide compositions
|
|
EP3359181A1
(en)
|
2015-10-07 |
2018-08-15 |
Cyprumed GmbH |
Pharmaceutical formulations for the oral delivery of peptide drugs
|
|
WO2017149070A1
(en)
|
2016-03-03 |
2017-09-08 |
Novo Nordisk A/S |
Glp-1 derivatives and uses thereof
|
|
WO2018065634A1
(en)
|
2016-10-07 |
2018-04-12 |
Cyprumed Gmbh |
Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
|
|
US11458201B2
(en)
*
|
2016-10-31 |
2022-10-04 |
Suda Ltd. |
Mucosal active agent delivery
|
|
AR112015A1
(es)
|
2017-06-09 |
2019-09-11 |
Novo Nordisk As |
Composiciones sólidas para administración oral
|
|
AR114353A1
(es)
|
2018-02-02 |
2020-08-26 |
Novo Nordisk As |
Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
|
|
SMT202200352T1
(it)
|
2018-04-05 |
2022-09-14 |
Sun Pharmaceutical Ind Ltd |
Analoghi del glp-1 innovativi
|
|
TWI829687B
(zh)
*
|
2018-05-07 |
2024-01-21 |
丹麥商諾佛 儂迪克股份有限公司 |
包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
|